Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
[Advanced]

The most recent version of this article was published on 1 January 2008

Thorax. Published Online First: 3 August 2007. doi:10.1136/thx.2007.082602
Copyright © 2007 BMJ Publishing Group Ltd & British Thoracic Society

This Article
Right arrow Full Text (Rapid PDF)
Right arrow web only appendix
Right arrow All Versions of this Article:
thx.2007.082602v1
63/1/72    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Young, A. C
Right arrow Articles by Naughton, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Young, A. C
Right arrow Articles by Naughton, M.

Papers

Randomised placebo-controlled trial of non-invasive ventilation for hypercapnia in cystic fibrosis

Alan C Young 1*, John Wilson 2, Tom Kotsimbos 1 and Matthew Naughton 3

1 The Alfred Hospital, Australia
2 Monash University, Australia
3 Alfred Hospital, Australia

* To whom correspondence should be addressed. E-mail: alan.young{at}med.monash.edu.au.

Accepted 2 July 2007


*   Abstract

Background: The clinical benefits of domiciliary non-invasive positive pressure ventilation (NIV) have not been established in cystic fibrosis (CF). We studied the effects of nocturnal NIV on quality of life (QoL), functional and physiological outcomes in CF subjects with awake hypercapnia (PaCO2> 45 mmHg).

Methods: In a randomised, placebo-controlled, crossover study eight CF subjects with mean (SD) age 37 (8) years, BMI 21.1 (2.6) kg/m2, FEV1 35 (8) % predicted and PaCO2 52 (4) mmHg received six weeks of nocturnal (1) air (placebo), (2) oxygen and (3) NIV. The primary outcome measures were CF-specific QoL, daytime sleepiness and exertional dyspnoea. Secondary outcome measures were awake and asleep gas exchange, sleep architecture, lung function and peak exercise capacity.

Results: Compared to air, NIV improved the chest symptom score in the CFQoL Questionnaire (mean difference, 10; 95% CI, 5 to 16; p=0.002) and the transitional dyspnoea index score (mean difference, 3.1; 95% CI, 1.2-5.0; p=0.01). It reduced maximum nocturnal PtcCO2 (mean difference, -17mmHg; 95%CI, -7 to -28 mmHg; p=0.005) and increased exercise performance on the Modified shuttle test (mean difference, 83m; 95% CI, 21 to 144m; p=0.02). NIV did not improve sleep architecture, lung function or awake PaCO2.

Conclusion: Six weeks of nocturnal NIV improves chest symptoms, exertional dyspnoea, nocturnal hypoventilation and peak exercise capacity in stable adult CF patients with awake hypercapnia. Further studies are required to determine whether or not NIV can improve survival.


Keywords: cystic fibrosis, hypercapnia, non-invasive ventilation, oxygen, quality of life




This article has been cited by other articles:


Home page
ThoraxHome page
P. G Noone
Non-invasive ventilation for the treatment of hypercapnic respiratory failure in cystic fibrosis
Thorax, January 1, 2008; 63(1): 5 - 7.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 BMJ Publishing Group Ltd & British Thoracic Society